US · Healthcare · Biotechnology
EPS came in at -1.54 against a street estimate of -1.58 — a beat of 2.5%.
Analysts rate Disc Medicine Inc. a strong buy (11 buy, 0 hold, 0 sell out of 11) with an average price target of $101.00.
| Fund | Stake |
|---|---|
| FMR Inc | 14.63% |
| RA Capital Management, LLC | 6.41% |
| BlackRock Inc | 5.95% |
| Wellington Management Company LLP | 4.54% |
| State Street Corp | 4.45% |
| T. Rowe Price Associates, Inc. | 4.06% |
| Atlas Venture Life Science Advisors, LLC | 3.96% |
| Vanguard Capital Management, LLC | 3.60% |
| Document | Date |
|---|---|
| Quarterly report · Q2 2026 | 2026-07-30 |
| Results announced · Q3 2026 | 2026-07-30 |
| Material agreement · Q2 2026 | 2026-06-30 |
| Shareholder vote results · Q2 2026 | 2026-06-24 |
| Quarterly report · Q1 2026 | 2026-05-05 |
| Results announced · Q2 2026 | 2026-05-05 |
| Proxy statement · Q2 2026 | 2026-04-28 |
| Annual report FY2025 | 2026-02-26 |
Readable in the app.
Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Disc Medicine Inc. — free to start.
Google PlayApp StoreData updated 2026-08-05.